Janus Henderson Global Life Sciences Fund Class D (JNGLX) is a Health fund with $4.11 Billion in assets. The fund allocates 41.04% of its portfolio to its top 10 holdings. It primarily invests in averagemarketcap cap stocks , with a focus on the cash and equivalents sector.
The largest holding in the fund is Eli Lilly Co. COM NPV at 8.31% of total assets. This is followed by UnitedHealth Group Inc. COM USD0.01 (4.21%) and Novo Nordisk A/S SER'B'DKK0.1 (5.95%).
| Name | Weight | Owned | Change |
|---|---|---|---|
| Eli Lilly Co. COM NPV | 8.31% | - | - |
| UnitedHealth Group Inc. COM USD0.01 | 4.21% | - | - |
| Novo Nordisk A/S SER'B'DKK0.1 | 5.95% | - | - |
| AstraZeneca PLC ORD USD0.25 | 4.22% | - | - |
| AbbVie Inc. COM USD0.01 | 3.58% | - | - |
| Merck Co., Inc COM USD0.50 | 3.28% | - | - |
| Amgen Inc. COM USD0.0001 | 2.89% | - | - |
| Sanofi EUR2 | 3.05% | - | - |
| Boston Scientific Corporation COM USD0.01 | 2.74% | - | - |
| Vertex Pharmaceuticals Incorporated COM USD0.01 | 2.81% | - | - |
| Johnson Johnson COM USD1.00 | 5.01% | - | - |
| Abbott Laboratories COM NPV | 3.16% | - | - |
| Argenx SE SPON ADR EACH REP 1 ORD SHS | 2.82% | - | - |
| Sanofi SA EUR2 | 2.69% | - | - |
| Novartis AG ADR-REP 1 CHF0.5 (REGD) | 2.56% | - | - |